Summary
BeOne Medicines Ltd. (ONC) reported two significant developments via press releases filed with their 8-K on April 12, 2022. The first announcement concerns the validation of marketing authorization applications (MAA) for tislelizumab by the European Medicines Agency (EMA). These applications are for tislelizumab's use in treating advanced or metastatic esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancers (NSCLC) in patients who have previously undergone systemic chemotherapy. This validation marks a crucial step towards potential European market access for tislelizumab in these indications. The second key announcement highlights the positive results from the Phase 3 ALPINE trial for BRUKINSA® (zanubrutinib). The trial demonstrated that zanubrutinib, a BTK inhibitor, showed superiority over ibrutinib in achieving an overall response rate (ORR) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). These findings suggest a potentially improved treatment option for patients suffering from these blood cancers.
Key Highlights
- 1European Medicines Agency (EMA) validated marketing authorization applications (MAA) for tislelizumab for ESCC and NSCLC.
- 2Tislelizumab's MAA submissions were made by Novartis, the European license holder.
- 3Regulatory review by the EMA for tislelizumab in ESCC and NSCLC has officially commenced.
- 4Phase 3 ALPINE trial results for BRUKINSA® (zanubrutinib) were announced.
- 5BRUKINSA® demonstrated superiority over ibrutinib in Overall Response Rate (ORR) in relapsed/refractory CLL/SLL.
- 6The ALPINE trial's positive results were based on an Independent Review Committee (IRC) assessment.